Niagen Bioscience (NAGE) Stock Looks Reasonable On Earnings Yet Weak On Broader Checks

Niagen Bioscience stock has fallen sharply over the past year, yet over three years the share price is still ahead, leaving investors weighing a mixed valuation picture rather than a clear bargain or clear stretch.

• The stock is up about 109.3% over three years, which puts the recent pullback in a different light for anyone looking beyond the latest slump.
• The launch of a rare disease drug program may support expectations for future revenue, while the high-risk nature of pharmaceutical development can limit how much value investors are willing to assign to those plans today.
• On Simply Wall St's broader checks, Niagen Bioscience scores 4 out of 6 on valuation, pointing to a mixed read rather than clearly cheap or clearly expensive.

The issue now is whether the current price already reflects the balance between Niagen Bioscience's recent setbacks and its longer term potential from the new drug program.

Find out why Niagen Bioscience's -70.0% return over the last year is lagging behind its peers.

Does Niagen Bioscience Look Fairly Valued on Earnings?

P/E is a useful lens for Niagen Bioscience because the company currently reports positive earnings that can anchor the multiple. The stock trades on a P/E of about 14.5x, compared with roughly 18.6x for the wider Personal Products industry and around 21.7x for its closest peers, so the market is pricing Niagen Bioscience below both of those benchmarks.

The Fair P/E Ratio, which reflects what investors might typically pay for a business with Niagen Bioscience’s profile, is estimated at about 13.3x and is only slightly below the current market multiple. Despite the recent attention around its rare disease drug program, the share price still sits close to this tailored fair value marker rather than at a marked discount or premium.

Overall, Niagen Bioscience appears roughly fairly valued on its P/E multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The Niagen Bioscience Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Niagen Bioscience build on the valuation puzzle by explaining which assumptions about Niagen Bioscience's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. These Narratives are available on the Community page. Each Narrative links a fair value estimate to a clear storyline about the company's possible catalysts and risks, allowing you to track which version appears to be unfolding over time.

One of the top community narratives on Niagen Bioscience: 73% undervalued

"Expansion into the pharmaceutical-grade Niagen ingredient market, including the launch of Niagen IV and injections at clinics, could influence future revenue due to changing demand and potential resolution of supply chain issues…"

Read one of the top narratives on Niagen Bioscience

Do you think there's more to the story for Niagen Bioscience? Head over to our Community to see what others are saying!

The Bottom Line

For Niagen Bioscience, the current P/E suggests the stock is priced roughly in line with what the market is willing to pay for similar businesses, so it no longer stands out as clearly cheap or clearly expensive. The broader valuation checks point to a mixed picture, which fits a company balancing an established earnings base with a high risk rare disease program that is still early. The crux for investors is whether that program ultimately supports the existing multiple or exposes it, turning today’s seemingly reasonable pricing into either a value trap or a starting point for a re rating.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com